GRAIL (NASDAQ:GRAL) Announces Quarterly Earnings Results, Beats Estimates By $0.10 EPS

GRAIL (NASDAQ:GRAL) announced its quarterly earnings results on Wednesday. The company reported ($2.56) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.66) by $0.10, FiscalAI reports. The firm had revenue of $44.69 million for the quarter, compared to analyst estimates of $42.39 million. GRAIL had a negative net margin of 253.22% and a negative return on equity of 16.42%.

Here are the key takeaways from GRAIL’s conference call:

• Galleri sales continued to grow: Second-quarter screening revenue rose 24% year over year to $42.6 million, while test volume increased 35% to more than 61,000. The company added approximately 1,000 ordering providers and said growth is coming from brick-and-mortar physicians, digital health partners, employers, and payer partnerships.
• FDA review remains on track: GRAIL expects an FDA advisory committee meeting in fall 2026 and continues to anticipate potential approval in the first part of 2027. Management said the PMA review is progressing through an iterative process and that it is preparing for the advisory committee.
• Clinical data showed strong detection and safety metrics: Management highlighted false-positive rates below 0.5%, positive predictive values of 50% to 60%, and substantially higher cancer detection when Galleri was added to standard screening. The company also emphasized that roughly 40% to 50% of detected cancers were stage I or II, although the NHS-Galleri trial did not meet its primary endpoint for reducing stage III and IV cancers.
• Samsung financing supports international expansion: GRAIL completed a $110 million strategic investment from Samsung and began planning commercialization in South Korea, with potential expansion to Japan and Singapore. Management said discussions around distribution and longer-term collaboration are just beginning.
• Investment and pricing pressures remain: Adjusted EBITDA loss widened 15% year over year to $90.3 million, while average selling price declined because of greater digital-health volume and lower employer pricing. An Illumina royalty expected to resume toward the end of the fourth quarter will also create a future margin headwind, though management expects minimal Q4 impact.

GRAIL Stock Performance

Shares of NASDAQ GRAL traded down $10.94 during trading on Thursday, hitting $63.24. 1,044,384 shares of the company traded hands, compared to its average volume of 929,983. GRAIL has a fifty-two week low of $29.95 and a fifty-two week high of $118.84. The business’s fifty day moving average is $66.97 and its 200 day moving average is $66.72. The firm has a market capitalization of $2.71 billion, a price-to-earnings ratio of -6.09 and a beta of 3.24.

Analysts Set New Price Targets

GRAL has been the topic of several recent analyst reports. Robert W. Baird set a $70.00 target price on shares of GRAIL in a report on Wednesday, May 6th. The Goldman Sachs Group started coverage on shares of GRAIL in a research report on Friday, June 5th. They set a “neutral” rating and a $60.00 price objective for the company. Mizuho raised their target price on GRAIL from $58.00 to $65.00 and gave the company a “neutral” rating in a report on Wednesday, July 15th. Wolfe Research initiated coverage on GRAIL in a report on Tuesday, June 2nd. They set a “peer perform” rating for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of GRAIL in a research note on Friday, July 17th. Four equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $67.78.

Insiders Place Their Bets

In other GRAIL news, insider Andrew John Partridge sold 1,491 shares of GRAIL stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $61.08, for a total transaction of $91,070.28. Following the completion of the transaction, the insider owned 163,738 shares in the company, valued at approximately $10,001,117.04. The trade was a 0.90% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 1.83% of the company’s stock.

Institutional Trading of GRAIL

Institutional investors and hedge funds have recently made changes to their positions in the company. Virtu Financial LLC bought a new position in shares of GRAIL during the 4th quarter worth approximately $370,000. T. Rowe Price Investment Management Inc. bought a new stake in GRAIL during the fourth quarter worth $7,414,000. Invesco Ltd. boosted its position in GRAIL by 1.0% in the fourth quarter. Invesco Ltd. now owns 137,967 shares of the company’s stock worth $11,809,000 after purchasing an additional 1,422 shares during the last quarter. Corient Private Wealth LLC grew its stake in GRAIL by 59.7% in the 4th quarter. Corient Private Wealth LLC now owns 9,233 shares of the company’s stock valued at $790,000 after purchasing an additional 3,450 shares during the period. Finally, Mercer Global Advisors Inc. ADV bought a new stake in shares of GRAIL during the 4th quarter worth $303,000.

GRAIL Company Profile

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.